3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Ovarian Neoplasms
39
Breast Neoplasms
24
Neoplasms
12
Prostatic Neoplasms
11
Triple Negative Breast Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Pancreatic Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Ovarian Epithelial
6
Stomach Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Fanconi Anemia, Complementation Group D1
5
Small Cell Lung Carcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Solid Tumors
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Colorectal Neoplasms
2
Carcinoma
2
Advanced Solid Tumours
2
Advanced Solid Tumor
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Diseases
1
Platinum-sensitive Ovarian Cancer
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Interventions
olaparib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Solid Tumor, Adult
×
olaparib
×
Clear all
NCT04972110
2025-10-30
ATTACC
Repare Therapeutics
Phase 1/2
Terminated
156 enrolled
19 charts